AtaiBeckley Inc. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
4.160
+0.040 (0.97%)
At close: Apr 30, 2026, 4:00 PM EDT
4.200
+0.040 (0.96%)
Pre-market: May 1, 2026, 7:00 AM EDT
AtaiBeckley Revenue
In the year 2025, AtaiBeckley had annual revenue of $4.09M with 1,227.60% growth. AtaiBeckley had revenue of $1.07M in the quarter ending December 31, 2025.
Revenue (ttm)
$4.09M
Revenue Growth
+1,227.60%
P/S Ratio
373.29
Revenue / Employee
$41,303
Employees
99
Market Cap
1.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.09M | 3.78M | 1,227.60% |
| Dec 31, 2024 | 308.00K | -6.00K | -1.91% |
| Dec 31, 2023 | 314.00K | 81.00K | 34.76% |
| Dec 31, 2022 | 233.00K | -20.14M | -98.86% |
| Dec 31, 2021 | 20.38M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 407.32M |
| Immunocore Holdings | 400.02M |
| Monte Rosa Therapeutics | 123.67M |
| Vir Biotechnology | 68.56M |
| Intellia Therapeutics | 67.67M |
| Nuvation Bio | 62.90M |
| Immatics | 56.67M |
| Nanobiotix | 38.27M |
ATAI News
- 3 days ago - AtaiBeckley Transcript: Needham Virtual Psychedelics Forum - Transcripts
- 4 days ago - AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research - GlobeNewsWire
- 9 days ago - AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder - GlobeNewsWire
- 10 days ago - AtaiBeckley Stock Skyrockets As Psychedelic Rally Extends On Trump Fast‑Track Order - Benzinga
- 10 days ago - How Trump's psychedelics executive order could unlock stalled cannabis reform - CNBC
- 10 days ago - Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research - Forbes
- 10 days ago - Psychedelic stocks rally with Trump's support - Market Watch
- 10 days ago - Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring. - Barrons